Antibodies and chimeric antigen receptors that target TACI
AssigneeThe General Hospital Corporation
InventorsMarcela V. Maus, Rebecca Larson
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies, antibody-drug conjugates, bispecific T cell engagers (BiTEs), and chimeric antigen receptors (CARs) that target transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Such antibodies, antibody-drug conjugates, BiTEs, and CARs can be used, e.g., in methods for treating a cancer (e.g., multiple myeloma), an autoimmune disorder (e.g., characterized by a high titer of antibodies contributing to the disorder), or a plasma cell disease disorder (e.g., plasma cell dyscrasias) in a subject in need thereof.
Claims10
An antibody that specifically binds to transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), wherein the antibody comprises:
- (i) a heavy chain complementarity-determining region 1 (CDR-H1), a heavy chain complementarity-determining region 2 (CDR-H2), and a heavy chain complementarity-determining region 3 (CDR-H3) of a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 1;
- and
- (ii) a light chain complementarity-determining region 1 (CDR-L1), a light chain complementarity-determining region 2 (CDR-L2), and a light chain complementarity-determining region 3 (CDR-L3) of a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.